Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B
Ben Samelson-Jones/LinkedIn
Mar 18, 2026, 12:17

Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B

Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“Sustained long term safety and efficacy (up to 6 years) with AAV gene therapy using FIX-Padua for hemophilia B.”

Title: Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B

Authors: Benjamin J Samelson-Jones, John EJ Rasko, Jonathan Ducore, Catherine McGuinn, Lindsey A. George, Sylvia von Mackensen, Gianluca Borgonuovo, Delphine Agathon, Lynne Smith, Lisa J Wilcox, Francesca Biondo, Frank Plonski

Read the Full Article on Blood Advances

Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B

 

Stay updated on all scientific advances with Hemostasis Today.

 

AAV Gene Therapy Benjamin J. Samelson–Jones Catherine McGuinn Delphine Agathon FIX Padua Francesca Biondo Frank Plonski Gianluca Borgonuovo Health Hematology Hemophilia B Hemostasis News Hemostasis Today John EJ Rasko Jonathan Ducore Lindsey A. George Lisa J Wilcox Lynne Smith Medicine Sylvia von Mackensen
NewsFeed